Johnson & Johnson reported slightly lower sales and adjusted EPS, but maintained its guidance and highlighted strategic initiatives and cost controls. While there are ongoing challenges from generic competition and healthcare reform, the stable guidance and management's confident tone suggest no immediate stock impact in the short term.

[0]